In 2010, the FDA mandated that 4 companies marketing long-acting β2 agonists perform trials comparing the safety of combination therapy with LABA plus an inhaled glucocorticoid vs an inhaled glucocorticoid...
Aristada recently received approval from the US Food and Drug Administration for a new and shorter dosing regimen, providing more options to patients and health care providers.
